The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and feasibility of JAK inhibitor ruxolitinib in newly-diagnosed high-grade gliomas (CRUX): Final toxicity report.
 
Manmeet Singh Ahluwalia
Stock and Other Ownership Interests - CytoDyn; doctible; MedInnovate Advisors LLC; MimiVax
Honoraria - Elsevier; Peerview; Prime Education; Prime Oncology
Consulting or Advisory Role - Anheart Therapeutics; Apollomics; Bayer; Bugworks; Cairn Therapeutics; Caris Life Sciences; GlaxoSmithKline; InSightec; Janssen; Menarini Group; Modifi Bio; NH TherAguix; Nuvation Bio; Prelude Therapeutics; Pyramid Biosciences; SDP Oncology; ViewRay; Voyager Therapeutics; Xoft
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Merck (Inst); MimiVax (Inst); Novartis (Inst); Novocure (Inst); Pharmacyclics (Inst); Seagen (Inst)
 
Ahmad Ozair
No Relationships to Disclose
 
Atulya Aman Khosla
No Relationships to Disclose
 
Yasmeen Rauf
No Relationships to Disclose
 
Wei Wei
No Relationships to Disclose
 
Erin Sennett Murphy
No Relationships to Disclose
 
Samuel T. Chao
No Relationships to Disclose
 
John H. Suh
Consulting or Advisory Role - Novocure; Philips, Inc.
 
Glen Stevens
No Relationships to Disclose
 
David M. Peereboom
Consulting or Advisory Role - Novocure; Orbus Therapeutics; Stemline Therapeutics; Sumitomo Dainippon Pharma Oncology, Inc.
Research Funding - Apollomics (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Global Coalition for Adaptive Research (Inst); Karyopharm Therapeutics (Inst); MimiVax (Inst); Mylan (Inst); Neonc Technologies (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Orbus Therapeutics (Inst); Pfizer (Inst); Pharmacyclics (Inst); Vigeo Therapeutics (Inst)
Other Relationship - IN8bio (Inst)